Tissue Inhibitor of Metalloproteinases 2 Level in Patients Undergoing Cardiac Surgery
Launched by WUHAN UNIVERSITY · Mar 7, 2025
Trial Information
Current as of April 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients (≥18 years old) underwent on-pump cardiac surgery
- • admitted to ICU immediately after surgery
- Exclusion Criteria:
- • Patients younger than 18 years
- • with prior AKI
- • end-stage kidney disease
- • need for chronic hemodialysis
- • pregnant patients
- • unable to give written consent for participation
About Wuhan University
Wuhan University, a prestigious research institution located in Wuhan, China, is renowned for its commitment to advancing medical science and improving public health through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive academic resources and expertise to conduct rigorous clinical studies aimed at exploring novel therapies and interventions. The institution is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring the safety and well-being of participants while contributing valuable insights to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
